Publications by authors named "Thomas Buhl"

17Publications

ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.

Authors:
Markus R John Leo Widler Rainer Gamse Thomas Buhl Klaus Seuwen Werner Breitenstein Gerard J M Bruin Rossella Belleli Lloyd B Klickstein Michaela Kneissel

Bone 2011 Aug 14;49(2):233-41. Epub 2011 Apr 14.

Novartis Pharma AG, Basel, Switzerland.

View Article and Find Full Text PDF
August 2011

Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists).

Authors:
Marc Gerspacher Eva Altmann René Beerli Thomas Buhl Ralf Endres Rainer Gamse Jacques Kameni-Tcheudji Michaela Kneissel Karl Heinz Krawinkler Martin Missbach Alfred Schmidt Klaus Seuwen Sven Weiler Leo Widler

Bioorg Med Chem Lett 2010 Sep 3;20(17):5161-4. Epub 2010 Aug 3.

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

View Article and Find Full Text PDF
September 2010

1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.

Authors:
Leo Widler Eva Altmann René Beerli Werner Breitenstein Rochdi Bouhelal Thomas Buhl Rainer Gamse Marc Gerspacher Christine Halleux Markus R John Hansjoerg Lehmann Oskar Kalb Michaela Kneissel Martin Missbach Irene R Müller Sibylle Reidemeister Johanne Renaud Agnes Taillardat Ruben Tommasi Sven Weiler Romain M Wolf Klaus Seuwen

J Med Chem 2010 Mar;53(5):2250-63

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2010

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Authors:
Marc Gerspacher Pascal Furet Carole Pissot-Soldermann Christoph Gaul Philipp Holzer Eric Vangrevelinghe Marc Lang Dirk Erdmann Thomas Radimerski Catherine H Regnier Patrick Chene Alain De Pover Francesco Hofmann Fabienne Baffert Thomas Buhl Reiner Aichholz Francesca Blasco Ralf Endres Jörg Trappe Peter Drueckes

Bioorg Med Chem Lett 2010 Mar 21;20(5):1724-7. Epub 2010 Jan 21.

Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2010

2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.

Authors:
Eva Altmann Reiner Aichholz Claudia Betschart Thomas Buhl Jonathan Green Osamu Irie Naoki Teno René Lattmann Marina Tintelnot-Blomley Martin Missbach

J Med Chem 2007 Feb 27;50(4):591-4. Epub 2007 Jan 27.

Novartis Institutes of BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
February 2007

Community maturity, species saturation and the variant diversity-productivity relationships in grasslands.

Authors:
Qinfeng Guo Terry Shaffer Thomas Buhl

Ecol Lett 2006 Dec;9(12):1284-92

View Article and Find Full Text PDF
December 2006

A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.

Authors:
Philipp Janser Ulf Neumann Wolfgang Miltz Roland Feifel Thomas Buhl

Bioorg Med Chem Lett 2006 May 3;16(10):2632-6. Epub 2006 Mar 3.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
May 2006

Dipeptide nitrile inhibitors of cathepsin K.

Authors:
Eva Altmann Reiner Aichholz Claudia Betschart Thomas Buhl Jonathan Green René Lattmann Martin Missbach

Bioorg Med Chem Lett 2006 May 9;16(9):2549-54. Epub 2006 Feb 9.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
May 2006

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.

Authors:
Laszlo Revesz Ernst Blum Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Ulf Neumann Gerard Rucklin

Bioorg Med Chem Lett 2006 Jan 24;16(2):262-6. Epub 2005 Oct 24.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
January 2006

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.

Authors:
Rudolf Waelchli Birgit Bollbuck Christian Bruns Thomas Buhl Jörg Eder Roland Feifel Rene Hersperger Philipp Janser Laszlo Revesz Hans-Günter Zerwes Achim Schlapbach

Bioorg Med Chem Lett 2006 Jan 19;16(1):108-12. Epub 2005 Oct 19.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
January 2006

Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.

Authors:
Laszlo Revesz Birgit Bollbuck Thomas Buhl Joerg Eder Ronald Esser Roland Feifel Richard Heng Peter Hiestand Benedicte Jachez-Demange Pius Loetscher Helmut Sparrer Achim Schlapbach Rudolf Waelchli

Bioorg Med Chem Lett 2005 Dec 28;15(23):5160-4. Epub 2005 Sep 28.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Autoimmunity and Transplantation, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
December 2005

Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.

Authors:
Johanne Renaud Serge François Bischoff Thomas Buhl Philipp Floersheim Brigitte Fournier Martin Geiser Christine Halleux Joerg Kallen Hansjoerg Keller Paul Ramage

J Med Chem 2005 Jan;48(2):364-79

Novartis Institute for Biomedical Research, WKL-136.6.81, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
January 2005

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.

Authors:
Laszlo Revesz Ernst Blum Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Gerard Rucklin

Bioorg Med Chem Lett 2004 Jul;14(13):3601-5

Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

Authors:
Laszlo Revesz Ernst Blum Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Gerard Rucklin

Bioorg Med Chem Lett 2004 Jul;14(13):3595-9

Novartis Institutes for BioMedical Research, Arthritis & Bone Metabolism, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.

Authors:
Johanne Renaud Serge François Bischoff Thomas Buhl Philipp Floersheim Brigitte Fournier Christine Halleux Joerg Kallen Hansjoerg Keller Jean-Marc Schlaeppi Wilhelm Stark

J Med Chem 2003 Jul;46(14):2945-57

Novartis Pharma Research, WKL-136.3.25, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2003

Complementary use of ion trap/time-of-flight mass spectrometry in combination with capillary high-pressure liquid chromatography: early characterization of in vivo metabolites of the cathepsin K inhibitor NVP-AAV490 in rat.

Authors:
Wolfgang Blum Thomas Buhl Eva Altmann Jürgen Kühnöl Philippe Ramstein Reiner Aichholz

J Chromatogr B Analyt Technol Biomed Life Sci 2003 Apr;787(2):255-70

Novartis Pharma AG, Research Department, Building WKL-121.200, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
April 2003

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Authors:
Laszlo Revesz Franco E Di Padova Thomas Buhl Roland Feifel Hermann Gram Peter Hiestand Ute Manning Romain Wolf Alfred G Zimmerlin

Bioorg Med Chem Lett 2002 Aug;12(16):2109-12

Arthritis and Bone Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
August 2002